Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Rituxan

(rih-TUK-sun)
A drug that contains the active ingredient rituximab and is used alone or with other drugs to treat adults and children aged 6 months and older with certain types of B-cell non-Hodgkin lymphoma, adults with chronic lymphocytic leukemia, and children aged 6 months and older with B-cell acute leukemia. It is used in patients whose cancer is CD20 positive. It is also being studied in the treatment of other conditions and types of cancer. Rituxan binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Rituxan is a type of monoclonal antibody.
More Information
Search NCI's Dictionary of Cancer Terms